-
$21.5M Series A financing round to advance pipeline of next-gen engineered off-the-shelf NK cell therapies
-
Funding round led by current investors Acorn Bioventures and ALSHC; joined by new investor Cormorant Asset Management
-
Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
What is Cord Tissue Banking?
Cord tissue banking is the processing and storage of a newborn’s umbilical cord tissue or the components contains, such as Wharton’s jelly. Wharton’s jelly is a thick, gelatinous substance present within the human umbilical cord that contains a range of important cell types, such as mesenchymal stem cells (MSCs), fibroblasts and macrophages.
In this article:
Cord Blood Banking – Present and Future Outlook
Cord blood banking is defined as the collection and storage of stem cells present within the umbilical cord blood of a newborn for future medical use. Umbilical cord blood is rich in a type of stem cell known as a hematopoietic stem cell (HSC). A large market for the storage of these cells has come into existence over the past 30 years, with public and private cord blood banks now present in all major healthcare markets worldwide. [Read more…]
Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells
CAMBRIDGE, Mass., Nov. 12, 2021 — Editas Medicine, Inc. (Nasdaq: EDIT), a genome editing company, announced preclinical data on its progress in the development of novel engineered induced pluripotent stem cell (iPSC)-derived natural killer cells (iNKs) for the treatment of cancer. In the presentation, the Company showed a new method to achieve high-levels of expression of CD16 and Interleukin-15 (IL-15) in iNK cells by using the Company’s proprietary CRISPR/Cas12a-mediated SLEEK (SeLection by Essential-gene Exon Knock-in) technology to simultaneously knock-in both functional genes. The modifications resulted in improved serial tumor killing and dramatically increased NK cell persistence. [Read more…]
Cord for Life®, Inc. Announces Cord Blood Clinical Trial Phase I Trial for the Treatment of Lower Back Pain of the Sacroiliac Joint
Altamonte Springs, FL, October 29, 2021 — Cord for Life®, a full-service cord blood bank with over 25 years of experience, today announced plans to conduct a clinical trial to treat lower back pain arising from the Sacroiliac Joint (SIJ) using a biological therapeutic derived from umbilical cord blood. [Read more…]
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 62
- Next Page »